MedTrace Logo

An Observational, Multicenter Study to Evaluate the Use and Effectiveness of Doptelet® in Patients With ITP

NCT04943042 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 199

Last updated 2025-07-14

No results posted yet for this study

Summary

This is a multi-center, observational, Phase 4 study in patients with Immune Thrombocytopenia (ITP) designed to describe the real-world effectiveness of Doptelet and assess the patterns of drug utilization to add to the knowledge base regarding the use of Doptelet in routine medical practice. Patients eligible for participation will, as part of their routine medical care, be receiving Doptelet for the treatment of ITP.

Conditions

Interventions

DRUG

Avatrombopag

According to prescription

Sponsors & Collaborators

  • Swedish Orphan Biovitrum

    lead INDUSTRY

Principal Investigators

  • Nina Skuban, MD · Swedish Orphan Biovitrum AB

  • Vickie McDonald, MD · Royal London Hospital, London, UK

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-22
Primary Completion
2025-06-10
Completion
2025-06-10

Countries

  • Croatia
  • Czechia
  • Germany
  • Italy
  • Netherlands
  • Norway
  • Spain
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04943042 on ClinicalTrials.gov